Shockwave Medical Reports Fourth Quarter and Full Year 2020 Financial Results

SANTA CLARA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2020.

Recent Highlights

  • Recognized revenue of $22.7 million for the fourth quarter of 2020 and $67.8 million for the full year of 2020, representing increases of 59% and 58%, respectively, from the same periods in 2019
  • Received FDA approval of IVL for severely calcified coronary artery disease
  • Presented data for two large trials at late breaking sessions in the fourth quarter
  • Granted four new codes by CMS that established specific payment for IVL procedures performed in an outpatient setting in arteries below the knee
  • Granted eight codes by CMS for IVL performed in Ambulatory Surgery Centers
  • Ended the year with over 100 issued patents

“The successes we achieved despite the myriad COVID challenges of 2020 are a testament to the team at Shockwave and to the clinical value of our proprietary IVL technology,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “With the recent FDA approval of our C2 device, we will now be able to address a significant unmet need for patients with severely calcified coronary arteries in the United States. I want to thank our employees and our investigators for their hard work and persistence as they have fought through the pandemic to put us in this fortunate position.”

Fourth Quarter 2020 Financial Results

Revenue for the fourth quarter of 2020 was $22.7 million, an increase of $8.4 million, or 59%, compared to the fourth quarter of 2019. The growth was primarily driven by sales force expansion in the U.S. and increased penetration in both U.S. and international markets.

Gross profit for the fourth quarter of 2020 was $16.2 million compared to $8.8 million for the fourth quarter of 2019. Gross margin for the fourth quarter of 2020 was 72%, as compared to 61% in the same period of last year. Contributors to gross margin expansion included continued improvement in manufacturing productivity and process efficiencies.

Operating expenses were $32.1 million for the fourth quarter of 2020 compared to $24.1 million in the corresponding prior year period, representing a 33% increase, primarily driven by increases in headcount since the year ago period.

Net loss was $15.9 million in the fourth quarter of 2020, as compared to $14.7 million in the corresponding period of the prior year. Net loss per share was $0.46 in the fourth quarter of 2020.

Full Year 2020 Financial Results

Revenue for full year 2020 was $67.8 million, an increase of $24.9 million, or 58%, compared to the full year of 2019. The growth was primarily driven by the expansion of the U.S. sales force and international distributor network.

Gross profit for the full year 2020 was $46.8 million compared to $25.8 million for the full year 2019. The gross margin percentage for the full year 2020 increased to 69% compared to 60% in the full year 2019, driven primarily by improvements in production processes and greater absorption of fixed costs by higher production.

Operating expenses were $112.5 million for the full year 2020 compared to $77.6 million in the prior year, an increase of 45%, primarily driven by headcount increases.

Net loss was $65.7 million for full year 2020, as compared to $51.1 million in the prior year. Net loss per share was $1.99 for full year 2020.

Cash, cash equivalents and short-term investments totaled $202.4 million as of December 31, 2020.

Impact of COVID-19 Pandemic and 2021 Financial Guidance

The COVID-19 pandemic continues to create significant uncertainty globally, including in relation to (i) the scope and duration of the current global resurgence of COVID-19 cases, (ii) the impact of new mutations of the virus, (iii) the timing and efficacy of COVID-19 vaccines, and (iv) the timing and extent of a global recovery and economic normalization. Given this continued uncertainty, we cannot provide reasonable guidance as to Shockwave Medical’s future results of operations and financial performance. As such, Shockwave is not issuing 2021 financial guidance at this time.

Conference Call

Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Wednesday, February 17, 2021 to discuss its fourth quarter and full year 2020 financial results. The call may be accessed through an operator by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 7854854. A live and archived webcast of the event will be available at

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit

Forward-Looking Statements

This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the impact of the COVID-19 pandemic on our operations, financial results, and liquidity and capital resources, including the impact on our sales, expenses, supply chain, manufacturing, research and development activities, clinical trials, and employees; our ability to develop, manufacture, obtain and maintain regulatory approvals for, market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; and our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in Part I, Item IA – Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, and in our other periodic and other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Media Contact:
Scott Shadiow

Investor Contact:
Debbie Kaster

Balance Sheet Data
(in thousands)

December 31,


December 31,

Cash and cash equivalents   $ 50,423     $ 139,045  
Short-term investments     151,931       56,304  
Accounts receivable, net     11,689       7,377  
Inventory     29,859       12,074  
Prepaid expenses and other current assets     2,398       1,897  
  Total current assets     246,300       216,697  
Operating lease right-of-use assets     7,568       8,825  
Property and equipment, net     16,362       4,910  
Other assets     1,812       1,506  
TOTAL ASSETS   $ 272,042     $ 231,938  
Accounts payable   $ 1,466     $ 2,790  
Term notes, current portion     3,300       6,667  
Accrued liabilities     19,942       13,777  
Lease liability, current portion     873       774  
  Total current liabilities     25,581       24,008  
Lease liability, noncurrent     7,488       8,125  
Term notes, noncurrent portion     13,319       7,152  
TOTAL LIABILITIES     46,388       39,285  
Preferred stock            
Common stock     35       31  
Additional paid-in capital     469,283       370,561  
Accumulated other comprehensive loss     9       35  
Accumulated deficit     (243,673 )     (177,974 )
TOTAL STOCKHOLDERS’ EQUITY     225,654       192,653  

Statement of Operations Data
(in thousands, except share and per share data)
    Three Months Ended
December 31,
  Year Ended
December 31,
      2020       2019       2020       2019  
Product revenue   $ 22,716     $ 14,312     $ 67,789     $ 42,927  
Cost of revenue:                
Cost of product revenue     6,471       5,553       20,991       17,159  
  Gross profit     16,245       8,759       46,798       25,768  
Operating expenses:                
Research and development     9,044       10,075       36,926       32,853  
Sales and marketing     16,436       9,597       51,672       30,620  
General and administrative     6,631       4,450       23,863       14,134  
  Total operating expenses     32,111       24,122       112,461       77,607  
Loss from operations     (15,866 )     (15,363 )     (65,663 )     (51,839 )
Interest expense     (315 )     (198 )     (1,212 )     (944 )
Change in fair value of warrant liability                       (609 )
Other income, net     314       827       1,256       2,345  
Net loss before taxes     (15,867 )     (14,734 )     (65,619 )     (51,047 )
Income tax provision     7       11       80       62  
  Net loss   $ (15,874 )   $ (14,745 )   $ (65,699 )   $ (51,109 )
Net loss per share, basic and diluted   $ (0.46 )   $ (0.49 )   $ (1.99 )   $ (2.14 )
Shares used in computing net loss per share, basic and diluted     34,447,314       29,894,306       33,088,095       23,904,828  


error: Content is protected !!